Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma

Hao, Yansheng; Khaykin, Daniel; Machado, Levi; Akker, Tayler van den; Houldsworth, Jane; Barlogie, Bart; Hussein, Shafinaz; Jamal, Siraj M. El; Petersen, Bruce; Teruya‐Feldstein, Julie

doi:10.1038/s41379-019-0333-6

Cited by 3 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, a new line of chemotherapy [cisplatin, doxorubicin, etoposide, cyclophosphamide] combined with pomalidomide and Carfilzomib was started for two cycles the patient planned for ASCT. 1, cases [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Upon an extensive review of English literature, a total of 22 cases of PCNs (including the three cases reported here) showed aberrant co-expression of Tcell associated markers.…”

Section: Results Results Of Patients Diagnosed In Our Centermentioning

confidence: 99%

“…Hao et al recently demonstrated that morphologic features, including plasmablastic morphology, and high mitotic index, significantly correlate with high risk disease. 16 Moreover, anaplastic myeloma variant, in which the malignant PCs are highly pleomorphic, has been reported more common in younger patients with a predisposition for the extramedullary site and poor prognosis. 14,17 This morphologic variant may present initially at diagnosis 16 or as a feature of disease progression.…”

Section: Discussion Aberrant Expression Of Differentiation Markers Of a Different Cell Lineage On The Malignantmentioning

confidence: 99%

See 1 more Smart Citation

Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival

Soliman

Elsabah

Ganwo

et al. 2021

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Background: Plasma cell neoplasms can show aberrant expression of a different lineage-related antigens, however, co-expression of T-cell associated markers on malignant plasma cells is extremely rare. Material and methods: This is a report of clinicopathologic characteristics of three myeloma patients with emergent plasmablastic morphology and aberrant acquisition of T‐cell associated markers. An extensive literature search for similar cases was conducted and the relevant pathologic, clinical and prognostic characteristics were summarized. Results: A total of 22 cases of plasma cell neoplasm, showed aberrant co-expression of T-cell markers. We found an evident association between aberrant expression of T-cell markers on malignant plasma cells and extramedullary involvement, aggressive morphologic features, high proliferative index ki67 >90%, aggressive clinical course, adverse outcome with short survival. Conclusion: Due to rarity of this aberrant phenotype and scarcity of the published data, the precise causative mechanism and its clinical implications have not yet been elucidated.

show abstract

Section: Results Results Of Patients Diagnosed In Our Centermentioning

confidence: 99%

Section: Discussion Aberrant Expression Of Differentiation Markers Of a Different Cell Lineage On The Malignantmentioning

confidence: 99%

Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival

Soliman

Elsabah

Ganwo

et al. 2021

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Patients with plasmablastic myeloma have a median survival significantly shorter than for the other cytologic categories. It has been recently demonstrated by Hao et al that bone marrow morphologic features, including diffuse sheet growth pattern, immature cell morphology, and high mitotic index, significantly correlates with high risk disease [6]. In approximately 2% of PCM cases, the morphology of the neoplastic cells is highly pleomorphic, and may resemble that of metastatic epithelial tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Plasma Cell Myeloma with an Aggressive Clinical Course and Anaplastic Morphology in a 22-Year-Old Patient: A Case Report and Review of Literature

et al. 2020

View full text Add to dashboard Cite

Unusual clinical course Background: Plasma cell myeloma is a neoplastic plasma cell disorder that usually presents after the fifth decade of life; it is rarely described in younger population especially under 30 years of age. However, there are conflicting reports in the literature about the clinical behavior and overall survival in younger age groups. In approximately 2% of plasma cell myeloma, the morphology of the neoplastic cells is highly pleomorphic, quite anaplastic, and may resemble metastatic tumor cells. While this poses a challenge for morphological interpretation during diagnosis, it has been demonstrated that bone marrow morphologic features (including diffuse sheet growth pattern, immature cell morphology and high mitotic index) significantly correlates with high risk disease. Moreover, there is limited description available about the morphology of the neoplastic cells when correlating the age at presentation with the clinical outcome/biological behavior; hence, the need to report and collect such cases. Case Report: We report a case of plasma cell myeloma in a 22-year-old male who presented with non-specific clinical features and posed a diagnostic challenge during clinical, radiological, and laboratory examination. The pathology specimens showed anaplastic morphology. Unfortunately, after diagnosis, despite treatment with brotezomib, his disease had an aggressive clinical course and he passed away 4 months after diagnosis. Conclusions: Although plasma cell myeloma is rare in patients younger than 30 years, it must be considered in the differential diagnosis and investigated properly especially in patients with clinical suspicion of a metastatic non-hematological tumor. The anaplastic variant in a young patient is a diagnostic challenge and is associated with bizarre morphology, aggressive presentation, adverse cytogenetics, resistance to chemotherapy, and poor, short-term, survival.

show abstract

“…2,4 The presence of t (11;14) confers unique morphological features in malignant plasma cells, including a lymphoplasmacytic phenotype with scant cytoplasm and expression of cyclin D1 and CD20. 5,6 Furthermore, t (11;14) MM cell lines have high expression of antiapoptotic protein BCL-2, with functional assays demonstrating the dependence of these cell lines on BCL-2 for survival. 7,8 Clinically, this translates into the potential of using targeted BCL-2-directed therapy such as venetoclax in this subgroup.…”

mentioning

confidence: 99%

“…Translocation t(11;14), which is characterized by the dysregulation of the cyclin D1 gene on chromosome 11q13, is the most common IgH translocation in MM and presents in 15% to 18% of newly diagnosed cases 2,4 . The presence of t(11;14) confers unique morphological features in malignant plasma cells, including a lymphoplasmacytic phenotype with scant cytoplasm and expression of cyclin D1 and CD20 5,6 . Furthermore, t(11;14) MM cell lines have high expression of antiapoptotic protein BCL‐2, with functional assays demonstrating the dependence of these cell lines on BCL‐2 for survival 7,8 .…”

mentioning

confidence: 99%

Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?

Chakraborty

Lentzsch

2020

Cancer

View full text Add to dashboard Cite

In this issue of Cancer, Badar et al report that African Americans with translocation t(11;14) multiple myeloma have excellent outcomes if they undergo early autologous hematopoietic cell transplantation followed by posttransplant maintenance, with the overall survival superior to White t(11;14) patients on multivariable analysis. Ongoing clinical trials on venetoclax‐based combination therapies in multiple myeloma should actively recruit minority populations such as Blacks, Asians, and Hispanics to identify any differential impact on outcomes.

show abstract

Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma

Cited by 3 publications

References 32 publications

Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival

Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival

Plasma Cell Myeloma with an Aggressive Clinical Course and Anaplastic Morphology in a 22-Year-Old Patient: A Case Report and Review of Literature

Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?

Contact Info

Product

Resources

About